	Application No.	Applicant(s)	
Notice of Allowability	Application No.	Applicant(s)	
	09/886,954	CHARRON ET AL.	
	Examiner	Art Unit	
	Gary B. Nickol Ph.D.	1642	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>09-12-05</u> .			
2. The allowed claim(s) is/are 6-11 and 16-20.			
<ul> <li>3. Acknowledgment is made of a claim for foreign priority unally all b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>	been received. been received in Application No		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
CORRECTED DRAWINGS ( as "replacement sheets") must (a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date  (b) ☐ including changes required by the attached Examiner's Paper No./Mail Date  Identifying Indicia such as the application number (see 37 CFR 1.)	on's Patent Drawing Review ( PTO-	ffice action of	
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
6. DEPOSIT OF and/or INFORMATION about the depo- attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAL m FOR THE DEPOSIT OF BIOLOGICA	nust be submitted. Note the AL MATERIAL.	
Attachment(s)			
1. Notice of References Cited (PTO-892)		5. Notice of Informal Patent Application (PTO-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		6.  ☐ Interview Summary (PTO-413), Paper No./Mail Date	
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date</li> </ol>	7. Examiner's Amendment/Comment		
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🗌 Examiner's Stateme	8. Examiner's Statement of Reasons for Allowance	
	9. Other		
Gu	ny fortulal	Gary B. Nickol Ph.D. Primary Examiner Art Unit: 1642	
GANY B. NICKUL, PH.D.		ALCOHIL 1042	
PRIMARY EXAMINER			

Page 2

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Alan Miller on September 12, 2005.

The claims have been amended as follows:

6. (currently amended) A method for determining whether a subject has a defect in cell

proliferation comprising assaying a diagnostic sample of the subject for GLUTx expression

wherein detection of GLUTx expression elevated above normal is diagnostic of a defect in cell

proliferation, wherein the defect in cell proliferation is a mammary adenocarcinoma or an

endometrial adenocarcinoma, wherein GLUTx protein has consists of the amino acid sequence

set forth in SEQ ID NO:1, and wherein the diagnostic sample is assayed using an antibody that

specifically binds to GLUTx protein.

8. (currently amended) A method for determining whether a subject has a defect in cell

proliferation comprising assaying a diagnostic sample of the subject for GLUTx expression

wherein detection of GLUTx expression elevated above normal is diagnostic of a defect in cell

proliferation, wherein the defect in cell proliferation is a mammary adenocarcinoma or an endometrial adenocarcinoma, wherein GLUTx protein has consists of the amino acid sequence set forth in SEQ ID NO:1, and wherein the diagnostic sample is assayed using at least one nucleic acid probe that specifically hybridizes to nucleic acid encoding GLUTx.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 571-272-0835. The examiner can normally be reached on M-Th, 8:30-5:30; alternate Fri., 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

> Gary B. Nickol Ph.D. **Primary Examiner** Art Unit 1642

**GBN** 

ARY B. NICKOL, PH.D. PRIMARY EXAMINER

Jany Brickol